✦ LIBER ✦

The promise and pitfalls of monoclonal antibody therapeutics

✍ Scribed by Ira Berkower

Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 647 KB
Volume: 7
Category: Article
ISSN: 0958-1669
DOI: 10.1016/s0958-1669(96)80073-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The therapeutic use of monoclonal antibo

The therapeutic use of monoclonal antibodies

✍ L. Chatenoud; J.F. Bach 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 508 KB

More pitfalls in the use of monoclonal a

More pitfalls in the use of monoclonal antibodies

✍ R. Jefferis; N.R. Ling 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 126 KB

The clinical pharmacology of therapeutic

The clinical pharmacology of therapeutic monoclonal antibodies

✍ Lorin K. Roskos; C. Geoffrey Davis; Gisela M. Schwab 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

## Abstract Seventeen monoclonal antibodies are currently approved in the United States for therapeutic use in organ transplantation, percutaneous coronary intervention, prophylaxis of respiratory syncytial virus disease, rheumatoid arthritis, Crohn's disease, asthma, chronic lymphocytic leukemia,

The promise and pitfalls of biopharming

📂 Article 📅 2008 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 83 KB

The immune response against therapeutic

The immune response against therapeutic monoclonal antibodies

✍ Lucienne Chatenoud 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 191 KB

Autoantibody potential of cancer therape

Autoantibody potential of cancer therapeutic monoclonal antibodies

✍ John A. McIntyre; and W. Page Faulk 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 315 KB

## Abstract We and others have reported that multiple autoantibodies are unmasked in human polyclonal antibody preparations after exposure to physiological oxidizing agents (hemin) or electromotive force. We now have asked if oxidation unmasks autoantibody reactivities in monoclonal antibodies (mAb